IceCure Medical Launches New $4.34M At-The-Market Offering

summarizeSummary

IceCure Medical has launched a new At-The-Market offering to sell up to $4.34 million in ordinary shares, providing critical capital for working capital and general corporate purposes.

check_boxKey Events

• New At-The-Market (ATM) Program

  IceCure Medical has established a new ATM offering program to sell up to $4,339,697 of ordinary shares through A.G.P./Alliance Global Partners. This formalizes the program announced via a 6-K on the same day.

• Significant Potential Dilution

  If all shares are sold at the assumed price of $0.24 per share (the last reported sale price on May 8, 2026), it would result in the issuance of approximately 18.1 million new shares, representing about 22% dilution to existing shareholders.

• Addresses Going Concern Warning

  The proceeds from this offering are intended for working capital and general corporate purposes, which is critical for the company following its recent 'going concern' disclosure in March 2026.

• Pricing Aligns with Market

  Shares will be sold at market prices, with the assumed offering price of $0.24 per share matching the last reported sale price on May 8, 2026.

auto_awesomeAnalysis

This filing details a new At-The-Market (ATM) offering program, allowing IceCure Medical to sell up to $4.34 million in ordinary shares. This capital raise is significant for the company, especially given its recent disclosure of substantial doubt about its ability to continue as a going concern. While dilutive, securing additional funding is crucial for extending the company's operational runway and addressing its working capital needs.